A detailed history of Emerald Advisers, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Emerald Advisers, LLC holds 91,561 shares of CYTK stock, worth $5.02 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
91,561
Holding current value
$5.02 Million
% of portfolio
0.27%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$63.75 - $108.06 $5.84 Million - $9.89 Million
91,561 New
91,561 $6.42 Million
Q1 2023

May 04, 2023

SELL
$33.36 - $45.71 $7.83 Million - $10.7 Million
-234,693 Reduced 49.69%
237,617 $8.36 Million
Q4 2022

Feb 03, 2023

BUY
$35.77 - $51.11 $4.71 Million - $6.73 Million
131,700 Added 38.67%
472,310 $21.6 Million
Q3 2022

Oct 25, 2022

BUY
$38.54 - $54.52 $7.57 Million - $10.7 Million
196,300 Added 136.03%
340,610 $16.5 Million
Q2 2022

Jul 29, 2022

BUY
$33.93 - $48.92 $4.9 Million - $7.06 Million
144,310 New
144,310 $5.67 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.16B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.